Avanir Pharmaceuticals Company Profile (NASDAQ:AVNR)

About Avanir Pharmaceuticals (NASDAQ:AVNR)

Avanir Pharmaceuticals logoAVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:AVNR
  • CUSIP: 05348P40
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $17.00
  • 200 Day Moving Avg: $15.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -106.00
  • P/E Growth: 0
Dividend:
  • Dividend Yield: 1.0%
 
Frequently Asked Questions for Avanir Pharmaceuticals (NASDAQ:AVNR)

What is Avanir Pharmaceuticals' stock symbol?

Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."

Who are some of Avanir Pharmaceuticals' key competitors?

How do I buy Avanir Pharmaceuticals stock?

Shares of Avanir Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avanir Pharmaceuticals' stock price today?

One share of Avanir Pharmaceuticals stock can currently be purchased for approximately $16.96.


MarketBeat Community Rating for Avanir Pharmaceuticals (NASDAQ AVNR)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Avanir Pharmaceuticals (NASDAQ:AVNR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Avanir Pharmaceuticals (NASDAQ:AVNR)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Avanir Pharmaceuticals (NASDAQ:AVNR)
Earnings by Quarter for Avanir Pharmaceuticals (NASDAQ:AVNR)
Earnings History by Quarter for Avanir Pharmaceuticals (NASDAQ AVNR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/5/2014Q314($0.08)($0.08)$29.46 million$28.60 millionViewListenView Earnings Details
5/6/2014Q214($0.08)($0.08)$28.21 million$26.95 millionViewListenView Earnings Details
2/5/2014Q114($0.08)($0.07)$24.84 million$26.70 millionViewListenView Earnings Details
12/10/2013Q4($0.07)($0.24)$21.86 million$21.70 millionViewListenView Earnings Details
8/6/2013Q3 2013($0.11)($0.08)$19.53 million$19.80 millionViewListenView Earnings Details
5/8/2013Q2 2013($0.09)($0.12)$17.40 million$17.40 millionViewListenView Earnings Details
2/7/2013Q1 2013($0.09)($0.09)$7.20 million$16.50 millionViewListenView Earnings Details
8/8/2012($0.11)($0.11)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/7/2012($0.13)($0.12)ViewN/AView Earnings Details
12/12/2011($0.16)($0.14)ViewN/AView Earnings Details
8/8/2011($0.13)($0.13)ViewN/AView Earnings Details
5/9/2011($0.14)($0.12)ViewN/AView Earnings Details
2/3/2011($0.14)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Avanir Pharmaceuticals (NASDAQ:AVNR)
Current Year EPS Consensus Estimate: $-0.31 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS

Dividends

Dividend History for Avanir Pharmaceuticals (NASDAQ:AVNR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Avanir Pharmaceuticals (NASDAQ:AVNR)
Insider Trades by Quarter for Avanir Pharmaceuticals (NASDAQ:AVNR)
Insider Trades by Quarter for Avanir Pharmaceuticals (NASDAQ:AVNR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/18/2014Christine OcampoVPSell35,780$16.94$606,113.20View SEC Filing  
12/18/2014Joao Md SiffertSVPSell15,505$16.93$262,499.65View SEC Filing  
12/17/2014Keith KatkinCEOSell277,680$16.95$4,706,676.00View SEC Filing  
11/28/2014Rohan PalekarSVPSell15,000$15.00$225,000.00View SEC Filing  
10/24/2014Christine OcampoVPSell2,080$11.81$24,564.80View SEC Filing  
10/24/2014Joao Md SiffertSVPSell8,426$11.80$99,426.80View SEC Filing  
10/24/2014Keith KatkinCEOSell27,567$11.76$324,187.92View SEC Filing  
9/15/2014Christine OcampoVPSell55,000$9.45$519,750.00View SEC Filing  
9/15/2014Rohan PalekarSVPSell25,000$11.50$287,500.00View SEC Filing  
8/1/2014Keith KatkinCEOSell9,670$5.26$50,864.20View SEC Filing  
5/16/2014Christine OcampoVPSell37,496$5.05$189,354.80View SEC Filing  
12/17/2013Rohan PalekarSVPBuy10,000$2.80$28,000.00View SEC Filing  
11/4/2013Rohan PalekarSVPBuy10,000$4.19$41,900.00View SEC Filing  
9/18/2013Joao Md SiffertSVPSell21,094$4.22$89,016.68View SEC Filing  
8/2/2013Keith KatkinCEOSell15,500$4.84$75,020.00View SEC Filing  
5/15/2013Christine OcampoVPSell77,700$3.29$255,633.00View SEC Filing  
5/15/2013Keith KatkinCEOSell250,438$3.26$816,427.88View SEC Filing  
12/13/2012Rohan PalekarSVPBuy10,000$2.46$24,600.00View SEC Filing  
12/3/2012Christine OcampoVPSell2,845$2.55$7,254.75View SEC Filing  
12/3/2012Keith KatkinCEOSell18,250$2.55$46,537.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Avanir Pharmaceuticals (NASDAQ:AVNR)
Latest Headlines for Avanir Pharmaceuticals (NASDAQ:AVNR)
Source:
DateHeadline
finance.yahoo.com logoReport: KC-area docs who were paid the most by drug, device companies
finance.yahoo.com - July 5 at 4:51 PM
finance.yahoo.com logoAvanir Pharmaceuticals Appoints Richard Malamut, MD, as Senior Vice President, Research & Development, and Chief Medical Officer
finance.yahoo.com - November 29 at 5:19 PM
finance.yahoo.com logoAvanir Pharmaceuticals to Present Data on ONZETRA™ Xsail™ at American Headache Society (AHS) 2016 Annual Scientific Meeting
finance.yahoo.com - June 9 at 5:30 PM
finance.yahoo.com logoNUEDEXTA® Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
finance.yahoo.com - June 8 at 8:00 PM
streetinsider.com logoAvanir Pharma (AVNR) Launches ONZETRA Xsail in the US - StreetInsider.com
www.streetinsider.com - May 16 at 1:45 PM
finance.yahoo.com logoAVANIR Pharmaceuticals Announces U.S. Launch and Availability of ONZETRA™ Xsail™ for the Acute Treatment of Migraine in Adults
finance.yahoo.com - May 16 at 9:00 AM
finance.yahoo.com logoAvanir Pharmaceuticals to Present Data on NUEDEXTA® and ONZETRA™ Xsail™ at American Academy of Neurology (AAN) 2016 Annual Meeting
finance.yahoo.com - April 15 at 5:19 PM
businesswire.com logoMC10, Inc. Appoints Eric K. Brandt to its Board of Directors - Business Wire (press release)
www.businesswire.com - April 1 at 9:49 PM
streetinsider.com logoAvanir Pharma (AVNR) Reports FDA Approval of ONZETRA to Treat Migraine - StreetInsider.com
www.streetinsider.com - January 29 at 10:10 AM
finance.yahoo.com logoAvanir Pharmaceuticals Announces FDA Approval of ONZETRA™ Xsail™ (AVP-825) for the Acute Treatment of Migraine in Adults
finance.yahoo.com - January 28 at 5:12 PM
prnewswire.com logoAcquisition of Avanir Pharmaceuticals, Inc. (AVNR) by Otsuka Pharmaceutical Co., Ltd. May Not Be in Shareholders' Best Interests
www.prnewswire.com - January 23 at 9:36 AM
nasdaq.com logoAvanir Pharma Names Rohan Palekar As President And CEO, Succeeding Katkin
www.nasdaq.com - January 21 at 4:54 PM
rttnews.com logoAvanir Pharma Names Rohan Palekar As President And CEO, Succeeding Katkin - RTT News
www.rttnews.com - January 20 at 9:43 AM
finance.yahoo.com logoAvanir Pharmaceuticals Announces Appointment of Rohan Palekar as President and Chief Executive Officer
finance.yahoo.com - January 20 at 8:30 AM
prnewswire.com logoAvanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion
www.prnewswire.com - January 16 at 6:06 PM
finance.yahoo.com logoAvanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms and Use of Antipsychotic Medications in Nursing Homes
finance.yahoo.com - December 1 at 8:30 AM
finance.yahoo.com logoAvanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
finance.yahoo.com - November 16 at 8:00 AM
finance.yahoo.com logoAvanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms in Retired Professional Football Players at the 12th Annual North American Brain Injury Society Conference
finance.yahoo.com - May 5 at 9:00 AM
finance.yahoo.com logoDanny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition
finance.yahoo.com - May 1 at 9:00 AM
finance.yahoo.com logoAvanir reports 4Q loss
finance.yahoo.com - January 5 at 2:46 PM
latimes.com logoJapanese firm Otsuka to buy Avanir Pharmaceuticals for $3.5 billion
www.latimes.com - December 2 at 8:39 PM
finance.yahoo.com logoEnergy companies lead an advance in US stocks
finance.yahoo.com - December 2 at 4:08 PM

Social

Chart

Avanir Pharmaceuticals (AVNR) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff